Emcure Pharmaceuticals Overview

  • Year Founded
  • 1981

Year Founded

  • Status
  • Public

  • Employees
  • 9,597

Employees

  • Stock Symbol
  • 544210

Stock Symbol

  • Investments
  • 13

  • Share Price
  • $25.04
  • (As of Friday Closing)

Emcure Pharmaceuticals General Information

Description

Emcure Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in developing, manufacturing, and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals, including solids, liquid orals, and dry syrup/suspensions; injectables such as vials and pre-filled syringes; and forms such as lyophilized & liquid, and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives categories. It has a single reportable operating segment, viz. Pharmaceuticals. Geographically, the company derives the maximum revenue from India, and the rest from Europe, North America, and other regions.

Contact Information

Website
www.emcure.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Plot Number P-1 and P-2, IT-BT Park, Phase II
  • M.I.D.C.,Hinjawadi
  • Pune, 411057
  • India
+91 020
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Vertical(s)
Corporate Office
  • Plot Number P-1 and P-2, IT-BT Park, Phase II
  • M.I.D.C.,Hinjawadi
  • Pune, 411057
  • India
+91 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Emcure Pharmaceuticals Stock Performance

As of 20-Nov-2026, Emcure Pharmaceuticals’s stock price is $25.04. Its current market cap is $4.75B with 190M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.04 $25.10 $15.03 - $25.69 $4.75B 190M 37.8K $0.62

Emcure Pharmaceuticals Financials Summary

As of 30-Sep-2026, Emcure Pharmaceuticals has a trailing 12-month revenue of $1.1B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 3,986,445 3,318,835 2,493,681
Revenue 1,103,776 1,031,632 923,430 795,062
EBITDA 223,897 206,410 175,791 147,316
Net Income 117,936 104,609 80,576 60,177
Total Assets 1,058,163 1,018,783 962,449 936,064
Total Debt 182,905 161,229 119,565 279,994
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Emcure Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Emcure Pharmaceuticals‘s full profile, request access.

Request a free trial

Emcure Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Emcure Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in developing, manufacturing, and globally market
Pharmaceuticals
Pune, India
9,597 As of 2026

Hyderabad, India
 

Bridgewater, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Emcure Pharmaceuticals Competitors (67)

One of Emcure Pharmaceuticals’s 67 competitors is Granules India, a Corporation company based in Hyderabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Granules India Corporation Hyderabad, India
Amneal Pharmaceuticals Formerly PE-Backed Bridgewater, NJ
Sun Pharmaceutical Industries Corporation Mumbai, India
Dr. Reddy's Corporation Hyderabad, India
Beximco Pharmaceuticals Corporation Dhaka, Bangladesh
You’re viewing 5 of 67 competitors. Get the full list »

Emcure Pharmaceuticals Patents

Emcure Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026154372-A1 Semaglutide in-situ gel formulation for parenteral administration Pending 16-Jan-2025
WO-2026133119-A1 Topical formulation for controlled delivery of active ingredient Pending 20-Dec-2024
WO-2026083220-A1 Cidofovir lipid based topical gel formulation Pending 18-Oct-2024
WO-2026033305-A1 Fused bicyclic heterocyclic derivatives as hdac inhibitors Pending 06-Aug-2024
EP-4812481-A1 Deuterated dydrogesterone Pending 22-Nov-2023 A61P15/00
To view Emcure Pharmaceuticals’s complete patent history, request access »

Emcure Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Emcure Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Emcure Pharmaceuticals‘s full profile, request access.

Request a free trial

Emcure Pharmaceuticals Investments & Acquisitions (13)

Emcure Pharmaceuticals’s most recent deal was a Merger/Acquisition with Gennova for . The deal was made on 17-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gennova 17-Jul-2026 Merger/Acquisition Drug Discovery
Cutimed 01-Apr-2026 Merger/Acquisition Personal Products
Zuventus Healthcare 03-Oct-2025 Secondary Transaction - Private Pharmaceuticals
Sunsure Solarpark Twelve 25-Jul-2024 Secondary Transaction - Private Energy Production
Zuventus Healthcare 07-Feb-2024 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Emcure Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

45.28 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Emcure Pharmaceuticals’s complete esg history, request access »

Emcure Pharmaceuticals Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Cutimed Boucherville, Canada 2011
Bharadwaj Pharma Hamburg, Germany 2009
Zuventus Healthcare Pune, India 2002
Gennova Pune, India 2001
Tillomed Laboratories Luton, United Kingdom 1990

Emcure Pharmaceuticals FAQs

  • When was Emcure Pharmaceuticals founded?

    Emcure Pharmaceuticals was founded in 1981.

  • Where is Emcure Pharmaceuticals headquartered?

    Emcure Pharmaceuticals is headquartered in Pune, India.

  • What is the size of Emcure Pharmaceuticals?

    Emcure Pharmaceuticals has 9,597 total employees.

  • What industry is Emcure Pharmaceuticals in?

    Emcure Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Emcure Pharmaceuticals a private or public company?

    Emcure Pharmaceuticals is a Public company.

  • What is Emcure Pharmaceuticals’s stock symbol?

    The ticker symbol for Emcure Pharmaceuticals is 544210.

  • What is the current stock price of Emcure Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Emcure Pharmaceuticals is $25.04.

  • What is the current market cap of Emcure Pharmaceuticals?

    The current market capitalization of Emcure Pharmaceuticals is $4.75B.

  • What is Emcure Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Emcure Pharmaceuticals is $1.1B.

  • Who are Emcure Pharmaceuticals’s competitors?

    Granules India, Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's, and Beximco Pharmaceuticals are some of the 67 competitors of Emcure Pharmaceuticals.

  • What is Emcure Pharmaceuticals’s annual earnings per share (EPS)?

    Emcure Pharmaceuticals’s EPS for 12 months was $0.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process